Trial Profile
An Open-Label, Multi-Dose, Phase I, Dose-Escalating Study of a Subcutaneously Administered Human-Engineered Monoclonal Antibody, ING-1(heMAb), in Subjects With Advanced Adenocarcinomas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs ING 1 (Primary)
- Indications Adenocarcinoma
- Focus Adverse reactions
- Sponsors XOMA
- 03 Jun 2014 New trial record